Tier 4 — mechanistic

Therapeutic potential of betaine and its derivatives in cancer treatment: a comprehensive review

Muhammad Shahzaib Hassan, Tanzila Khalid, Maida Akhlaq, Abdul Hameed, Faiza Sharif, Sobia Rana, Maliha Uroos
RSC advances 2025 15(26):20605-20622

Bibliography

PubMed
PMID 40530307
PubMed Central
PMC12172649
DOI
10.1039/d5ra00755k
Funding
Reported funding/support: University of the Punjab10.13039/100008696 Unassigned Higher Education Commission, Pakistan10.13039/501100004681 Unassigned
Competing interests
Reported disclosure: Authors declare no conflict of interest.

Study snapshot

DesignNarrative review
ModelEvidence synthesis; mixed research models
SamplePublished literature; no newly enrolled participant cohort
InterventionReview of betaine-related evidence; no single assigned intervention
DurationEvidence review; source-specific study durations vary
EndpointsBetaine biology; Clinical and mechanistic evidence

What the study showed, in plain terms

Published in 2025, this source examined mechanistic and clinical reviews. Its evidence base was Published literature; no newly enrolled participant cohort. It evaluated Review of betaine-related evidence; no single assigned intervention across Evidence review; source-specific study durations vary.

Reviews betaine and chemically modified derivatives in experimental cancer research.

Derivatives, delivery systems and cell/animal tumor models are not interchangeable with ordinary oral TMG or proven human cancer therapy.

Continue with TMG Data Center

Continue with TMG Supplement: Trimethylglycine Benefits, Uses and Evidence

Key findings

  • Reviews betaine and chemically modified derivatives in experimental cancer research.
  • The recorded outcome domains were Betaine biology; Clinical and mechanistic evidence.

What this study can and cannot tell us

  • Derivatives, delivery systems and cell/animal tumor models are not interchangeable with ordinary oral TMG or proven human cancer therapy.
  • The conclusions inherit the limitations of the underlying studies. A narrative interpretation or guideline recommendation is not a new randomized treatment comparison.
  • Source basis: Accessible full-text extract plus indexed bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 4
Association of choline and betaine levels with cancer incidence and survival: A meta-analysis
Jiyoung Youn et al. · Clinical nutrition (Edinburgh, Scotland) · 2019
Tier 4
Choline and betaine consumption lowers cancer risk: a meta-analysis of epidemiologic studies
Shanwen Sun et al. · Scientific reports · 2016
Tier 4
The association between dietary intakes of methionine, choline and betaine and breast cancer risk: A systematic review and meta-analysis
Heleen Van Puyvelde et al. · Cancer epidemiology · 2023
Tier 4
Decoding Betaine: A Critical Analysis of Therapeutic Potential Compared with Marketing Hype-A Narrative Review
Grzegorz Nikrandt et al. · The Journal of nutrition · 2024
Tier 4
Beneficial Effects of Betaine: A Comprehensive Review
Madan Kumar Arumugam et al. · Biology · 2021
Tier 4
Betaine in human nutrition
Stuart A S Craig et al. · The American journal of clinical nutrition · 2004

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology